FX.co ★ Genentech:Phase III Study Of Tiragolumab Combination In Advanced Lung Cancer Fails To Meet Main Goal

Genentech has announced the results of its Phase III SKYSCRAPER-01 study, which assessed the effectiveness of combining tiragolumab with Tecentriq (atezolizumab) against using Tecentriq alone in patients with PD-L1-high, locally advanced, or metastatic non-small cell lung cancer. Unfortunately, the study did not reach its primary goal of improving overall survival in the final analysis. Despite this, the safety profile remained consistent with extended observation, and no new safety concerns emerged.

As part of the Roche Group (RHHBY), Genentech remains committed to evaluating its study programs to determine if modifications are needed to inform future research initiatives. This approach will also apply to the tiragolumab program. More data from separate Phase III studies exploring various contexts or tumor types is expected next year.

The SKYSCRAPER-01 study is notable for being a global Phase III, randomized, double-blinded trial, investigating the combination of tiragolumab with Tecentriq compared to Tecentriq alone. It involved 534 patients with PD-L1-high, previously untreated, locally advanced unresectable or metastatic non-small cell lung cancer. Subjects were randomly assigned in a 1:1 ratio to receive either the tiragolumab and Tecentriq combination or a placebo with Tecentriq, continuing treatment until the disease progressed, clinical benefit was lost, or adverse toxicity became unacceptable.